Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences has demonstrated strong financial performance, with a projected revenue of $5.83 billion for 2025, reflecting a 9.2% year-over-year increase, largely driven by a $4.27 billion forecast for TAVR sales, which itself is anticipated to grow by 6.2% on an operational basis. The company's innovative products, including the PASCAL TMVr and EVOQUE Eos TMVR, are expected to significantly contribute to market growth, positioning Edwards to capture approximately 35% of the overall share alongside competitors. Additionally, the company's Q4 results revealed a TAVR sales figure of $1.04 billion, marking a remarkable 9.3% year-over-year increase, and underscoring a robust trajectory for both the U.S. and international markets despite some regional variances.

Edwards Lifesciences is facing significant challenges, with management anticipating Q1 2025 growth rates for both total company sales and transcatheter aortic valve replacement (TAVR) to fall below their respective guidance ranges, primarily attributed to having one less selling day. Additionally, a combination of macroeconomic pressures, slower adoption of TAVR, and heightened competition presents considerable revenue growth headwinds, further exacerbated by projected foreign exchange impacts expected to exceed $130 million. Overall, these factors contribute to a negative outlook regarding the stock's performance, as indicated by the downside revenue scenario analysis based on current valuation metrics.